Kenvue Inc. (NYSE:KVUE) Receives $24.42 Average Price Target from Analysts

Shares of Kenvue Inc. (NYSE:KVUE) have received an average rating of “Hold” from the thirteen brokerages that are covering the stock, MarketBeat Ratings reports. Eight research analysts have rated the stock with a hold rating and five have issued a buy rating on the company. The average 1 year price target among brokerages that have covered the stock in the last year is $24.42.

KVUE has been the topic of a number of research reports. Redburn Atlantic began coverage on shares of Kenvue in a research note on Thursday, April 10th. They issued a “neutral” rating and a $23.50 price target on the stock. Piper Sandler upped their price objective on Kenvue from $24.00 to $27.00 and gave the stock an “overweight” rating in a research report on Monday, February 24th. Evercore ISI initiated coverage on Kenvue in a research report on Monday, March 24th. They issued an “in-line” rating and a $25.00 target price on the stock. UBS Group cut their price objective on shares of Kenvue from $23.00 to $21.00 and set a “neutral” rating on the stock in a research report on Friday, February 7th. Finally, Canaccord Genuity Group lifted their price target on shares of Kenvue from $24.00 to $29.00 and gave the company a “buy” rating in a research note on Wednesday, March 5th.

Kenvue Stock Performance

Shares of Kenvue stock opened at $23.95 on Tuesday. The firm has a fifty day moving average of $23.08 and a two-hundred day moving average of $22.49. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00. The stock has a market capitalization of $45.94 billion, a price-to-earnings ratio of 45.18, a PEG ratio of 2.62 and a beta of 1.02. Kenvue has a 52 week low of $17.67 and a 52 week high of $24.46.

Kenvue (NYSE:KVUE) last issued its quarterly earnings data on Thursday, February 6th. The company reported $0.26 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. As a group, equities research analysts predict that Kenvue will post 1.14 EPS for the current year.

Kenvue Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, May 28th. Stockholders of record on Wednesday, May 14th will be issued a dividend of $0.205 per share. This represents a $0.82 annualized dividend and a dividend yield of 3.42%. The ex-dividend date is Wednesday, May 14th. Kenvue’s dividend payout ratio (DPR) is currently 154.72%.

Hedge Funds Weigh In On Kenvue

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Bard Financial Services Inc. boosted its holdings in Kenvue by 5.7% in the third quarter. Bard Financial Services Inc. now owns 106,790 shares of the company’s stock valued at $2,470,000 after acquiring an additional 5,750 shares during the last quarter. Boyar Asset Management Inc. boosted its position in Kenvue by 7.2% during the third quarter. Boyar Asset Management Inc. now owns 29,171 shares of the company’s stock valued at $675,000 after acquiring an additional 1,948 shares during the last quarter. Wilmington Savings Fund Society FSB bought a new position in shares of Kenvue in the 3rd quarter worth about $1,057,000. Tidal Investments LLC boosted its position in shares of Kenvue by 9.9% during the 3rd quarter. Tidal Investments LLC now owns 131,128 shares of the company’s stock valued at $3,033,000 after purchasing an additional 11,849 shares in the last quarter. Finally, Oddo BHF Asset Management Sas acquired a new stake in Kenvue during the third quarter worth approximately $1,570,000. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.